Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Lipids Market – Industry Trends and Forecast to 2030

Pharmaceutical | Published Report | Dec 2022 | North America | 350 Pages | No of Tables: 133 | No of Figures: 43

Report Description

North America Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and Others), Source (Egg Yolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2030.

Get Exclusive Sample Copy of this Report Here

North America Lipids Market Analysis and Insights 

The growing prevalence of chronic diseases globally has enhanced the demand of the market. The rising healthcare expenditure for better health services are also attributing in the growth of the market. The major market players are highly focusing on various product launches and drug approvals during this crucial period. In addition, the increasing demand for lipids in various other industries such as food and beverage, cosmetic industries and among others also contributing in the rising demand for lipids market.

Get Exclusive Sample Copy of this Report Here

Get Exclusive Sample Copy of this Report Here

The increasing healthcare expenditure, strategic initiatives by market players and are giving opportunities to the market. However, different manufacturing challenges for lipid nanoparticles production and lack of healthcare facilities in emerging economies are key challenges for the market growth.

North America lipids market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.5% in the forecast period of 2023 to 2030 and is expected to reach USD 10,817.54 million by 2030 from USD 5,654.25 million in 2022.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customisable to 2020-2015)

Quantitative Units

Revenue in USD Million

Segments Covered

By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and Others), Source (Egg Yolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries and Others), Distribution Channel (Direct Tender, Retail Sales and Others)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia North America Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry

Market Definition

Lipids can be defined as a group of organic compounds found in animals, plants, and micro- organisms. They include sterols, waxes, fats, and fat soluble vitamins. Lipids hold an ability to execute various activities. At the same time, they are known for having low toxicity levels. These qualities of lipids help in effective drug delivery. As a result, they are increasingly used as excipients in the drug production. This factor is fueling the growth of the North America pharmaceutical lipids market.

In recent period, the worldwide healthcare sector is going through remarkable changes. Development in drug delivery technology along with the incorporation of drug formularies is working as a driver for the growth of the pharmaceutical lipids market. Growth in quick chronic health issues and quick resulting drug delivery to the patient is one of the key factors pushing the growth of the North America pharmaceutical lipids market.

Lipids Market Dynamics

Drivers

  • Increase in the prevalence of chronic diseases

The encumbrance of chronic disease is briskly increasing across the globe. According to the WHO (World Health Organization), in 2021, the contribution of chronic disease was about 60%, which accounted for the number of deaths. In most Western countries, the major reason behind the increasing number of chronic diseases is the continuous increase in the aged population. The rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to an increase in the demand for various medicinal drugs that will drive the growth of the North America lipids market in the coming years.

  • Rising demand for lipids in food and beverage as well as the cosmetic industry

The demand for lipids in pharmaceuticals is very high as it is used in developing various drugs in the market. Also, the demand for lipids has increased in various other industries, such as in food & beverage and cosmetic products.

Lipids are an essential ingredient in the formulation of dietary supplements owing to their high content of energy and fat-soluble vitamins. Increasing health concern among people in light of COVID-19 has propelled the North America demand for dietary supplements. Furthermore, the availability of dietary supplements in multiple forms and flavours has made them more socially acceptable to all age groups. Growing dietary supplement consumption is expected to boost the demand for lipids over the projected years.

  • Rise in drug development

In the pharmaceutical industry, lipids and polymers are considered pillar excipients for formulating various drugs. They are used as stabilizers, solubilizes, permeation enhancers, and transfection agents. Increasing adoption of a wide range of natural, synthetic, semi-synthetic or completely artificial lipids and polymers in the formulation of various dosage forms is expected to boost the market over the forecast period.

Opportunities

  • Rise in healthcare expenditure

Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for various diseases is highly prevalent in recent years.

  • Strategic initiatives by major players

Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. Evonik invested in the short-term growth of its specialty lipids production at its Hanau and Dossenheim locations in Germany, which supplied two of the four lipids for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.

Restraints/Challenges

  • High cost of lipid synthesis and increasing cost of raw materials

Lipid based drugs require a huge cost for the development process. As the concept needs to be locked down, the materials need to be sourced, and it is important to consider lead times. Additionally, the process is time consuming as the drug needs sufficient time to fulfil all the clinical trials before bringing in the market for use.

Furthermore, any changes that must be re-verified will impact time. The growing advancements in biosensor assay formats and other complementary technologies demanded an effective investment for successful operations and a project risk management plan. The establishment of R&D for conducting research entails high costs, leading to expensive drugs. Thus, this factor is a major restraint for the North America lipids market.

  • Different manufacturing challenges for lipid nanoparticle production

Lipid nanoparticles have made a major impact on the pharmaceutical industry. At their core, lipid nanoparticles (LNPs) are delivery carriers that safeguard nucleic acids. As an integral part of recent mRNA vaccines, they are injected and transported to the intended site in the cell. Despite the many advantages of lipid nanoparticles as delivery systems, the pharmaceutical industry must address significant manufacturing challenges.

These challenges include:

  • Precisely controlled particle size/size distributions
  • Sterilization issues
  • Process repeatability and scalability
  • Regulatory requirements (such as cGMP regulations)

Post COVID-19 Impact on Lipids Market

The COVID-19 has positively affected the market. As the demand for COVID-19 vaccine was on the great demand and the positive point here is the lipid is majorly used in the vaccine production. Thus COVID-19 affected lipids market positively.

Recent Developments

  • In November 2022, BioNTech SE announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its North America footprint in Asia.
  • In September 2021, U.S. ingredients supplier ABITEC Corporation signed an amended agreement with DKSH to distribute its specialty lipids into new markets and regions across Europe. This has helped the company to expand its business in various regions.

North America Lipids Market Scope

North America lipids market is segmented into, type, lipid systems, delivery systems, source, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Natural Lipid
  • Synthetic Lipids

On the basis of type, the North America lipids market is segmented into natural lipid and synthetic lipid.

Lipid Systems

  • Bioactive Lipids 
  •   Polymerizable Lipids 
  •   Fluorescent Lipids 
  •   Bacterial Lipids 
  •   Neutral Lipids 
  •   Headgroup Modified Lipids 
  •   Others  

Based on lipid systems, the North America lipids market is segmented into neutral lipids, bacterial lipids, fluorescent lipids, bioactive lipids, polymerizable lipids, headgroup modified lipids and others.

Delivery Systems

  • Liposomes
  •  Solid Lipid Nanoparticles
  •  Nanostructures Lipid Carrier
  •  Transferosomes
  •  Niosomes
  •  Others

Based on delivery systems, the North America lipids market is segmented into liposomes, solid lipid nanoparticles, nanostructures lipid carrier, niosomes, transferosomes and others.

Source

  • Purified Fatty Acids 
  •   Purified Oils 
  •  Egg Yolk 
  •  Soyabean
  •   Non-GMO Soyabean 
  •  Others

Based on source, the North America lipids market is segmented into egg yolk, soyabean, non-GMO soyabean, purified oils, purified fatty acids and others.

End User

  • Pharmaceutical Industries
  • Biotechnology Industries
  • Cosmetic Industry
  • Academic and Research Institutes
  • Others

Based on end user, the North America lipids market is segmented into pharmaceutical industries, biotechnology industries, academic and research institutes, cosmetic industries and others.

Distribution Channel

  • Direct Tender
  • Retail Sales
  • Others

Get Exclusive Sample Copy of this Report Here

Based on distribution channel, the North America lipids market is segmented into direct tender, retail sales and others.

Lipids market Regional Analysis/Insights

The lipids market is analysed and market size insights and trends are provided by country, type, lipid systems, delivery systems, source, end user and distribution channel.

Countries covered in North America lipids market are U.S., Canada, and Mexico. U.S. dominates the lipids marketing terms of market share and market revenue and will continue to flourish its dominance during the forecast period.

The U.S. is expected to grow due to a rise in chronic diseases owing to high demand for pharmaceutical drugs and rising demand for lipids in different industries are expected to drive the regional market in the forecasted period.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Lipids Market Share Analysis

The lipids market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on premium wine market.

Some of the major players operating in the lipids market are Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia North America Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, Kerry, and among others.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA LIPIDS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 MERGER AND ACQUISITION, NORTH AMERICA LIPIDS MARKET

4.4 PATENT ANALYSIS, NORTH AMERICA LIPIDS MARKET

4.5 DRUG TREATMENT RATE BY MATURED MARKETS

4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE

4.7 KEY PRICING STRATEGIES

4.8 KEY PATIENT ENROLLMENT STRATEGIES

4.9 PRICE ANALYSIS, NORTH AMERICA LIPIDS MARKET

4.1 NORTH AMERICA LIPIDS MARKET, CLINICAL TRIALS

4.11 NORTH AMERICA LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE

4.12 NORTH AMERICA LIPIDS MARKET, PIPELINE ANALYSIS

4.13 PHASE I CANDIDATES

4.14 PHASE I/II CANDIDATES

4.15 PHASE II CANDIDATES

4.16 PHASE III CANDIDATES

5 NORTH AMERICA LIPIDS MARKET, REGULATORY FRAMEWORK

5.1 REGULATION IN THE U.S.:

5.2 REGULATION IN EUROPE:

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES

6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY

6.1.3 INCREASE IN DRUG DEVELOPMENT

6.2 RESTRAINTS

6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS

6.2.2 STRICT GOVERNMENT REGULATIONS

6.3 OPPORTUNITIES

6.3.1 RISE IN HEALTHCARE EXPENDITURE

6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION

6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES

7 NORTH AMERICA LIPIDS MARKET, BY TYPE

7.1 OVERVIEW

7.2 NATURAL LIPID

7.2.1 UNSATURATED PHOSPHOLIPID

7.2.2 HYDROGENATED PHOSPHOLIPID

7.2.3 SPHINGOMYELIN

7.2.4 GLYCEROLPHOSPHOCHOLINE

7.3 SYNTHETIC LIPID

7.3.1 PEGYLATED PHOSPHOLIPIDS

7.3.2 PHOSPHATIDYLSERINE

7.3.3 PHOSPHATIDYGLYCEROLS

7.3.4 PHOSPHATIDYLETHANOLAMINE

7.3.5 PHOSPHATIDYLCHOLINE

7.3.6 PHOSPHATIDIC ACIDS

8 NORTH AMERICA LIPIDS MARKET, BY LIPID SYSTEMS

8.1 OVERVIEW

8.2 BIOACTIVE LIPIDS

8.2.1 PLANT LIPIDS

8.2.2 LIPID ACTIVATORS

8.2.3 LIPID INHIBITORS

8.2.4 AGONISTS

8.2.5 BIOACTIVE CERAMIDES

8.2.6 ACYL CARNITINE LIPIDS

8.2.7 ENDOCANNABINOIDS

8.2.8 LIPO-NUCLEOTIDES

8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL

8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP)

8.3 POLYMERIZABLE LIPIDS

8.3.1 FUNCTIONAL PEG LIPIDS

8.3.2 MPEG STEROLS

8.3.3 MPEG CERAMIDES

8.3.4 MPEG PHOSPHOLIPIDS

8.3.5 MPEG GLYCERIDES

8.4 FLUORESCENT LIPIDS

8.4.1 FLUORESCENT SPHINGOLIPIDS

8.4.2 FLUORESCENT GLYCEROLIPIDS

8.4.3 FLUORESCENT PEG LIPIDS

8.4.4 FLUORESCENT PHOSPHOLIPIDS

8.4.5 FLUORESCENT STEROLS

8.4.6 OTHERS

8.5 BACTERIAL LIPIDS

8.5.1 MYCOLIC LIPIDS

8.5.2 N-ACYLHOMOSERINE LIPIDS

8.5.3 BRANCHED LIPIDS

8.5.4 CYCLOPROPYL LIPIDS

8.6 NEUTRAL LIPIDS

8.6.1 PRENOLS

8.6.2 VERY LONG CHAIN FATTY ACIDS

8.6.3 GLYCERIDES

8.6.4 EICSANOIDS

8.6.5 OXYGENATED FATTY ACIDS

8.6.6 GLYCOSYLATED DIACYL GLYCEROLS

8.6.7 PROSTAGLANDINS

8.7 HEADGROUP MODIFIED LIPIDS

8.7.1 FUNCTIONAL LIPIDS

8.7.2 ANTIGENIC LIPIDS

8.7.3 GLYCOSYLATED LIPIDS

8.7.4 CHELATORS

8.7.5 ADHESIVE LIPIDS

8.7.6 SNAP-TAG REACTING LIPIDS

8.7.7 ALKYL PHOSPHATES

8.8 OTHERS

9 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS

9.1 OVERVIEW

9.2 LIPOSOMES

9.2.1 LIPOSOMES FOR DNA/RNA

9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY

9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY

9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY

9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY

9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY

9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY

9.2.2 REACTIVE LIPOSOMES

9.2.2.1 SUCCINYL LIPOSOMES

9.2.2.2 DBCO LIPOSOMES

9.2.2.3 BIOTINYLATED LIPOSOMES

9.2.2.4 CARBOXYLIC ACID LIPOSOMES

9.2.2.5 AMINE LIPOSOMES

9.2.2.6 CYANUR LIPOSOMES

9.2.2.7 AZIDE LIPOSOMES

9.2.2.8 FOLATE LIPOSOMES

9.2.2.9 DODECANYL LIPOSOMES

9.2.2.10 NI REACTIVE LIPOSOMES

9.2.2.11 PDP LIPOSOMES

9.2.2.12 GLUTARYL LIPOSOMES

9.2.2.13 OTHERS

9.2.3 DRUG LOADED LIPOSOMES

9.2.4 PLAIN LIPOSOMES

9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES

9.2.4.2 DOTAP LIPOSOMES

9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES

9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES

9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES

9.2.4.6 OTHERS

9.3 SOLID LIPID NANOPARTICLES

9.4 NANOSTRUCTURES LIPID CARRIER

9.5 TRANSFEROSOMES

9.6 NIOSOMES

9.7 OTHERS

10 NORTH AMERICA LIPIDS MARKET, BY SOURCE

10.1 OVERVIEW

10.2 PURIFIED FATTY ACIDS

10.3 PURIFIED OILS

10.4 EGG YOLK

10.5 SOYABEAN

10.6 NON-GMO SOYABEAN

10.7 OTHERS

11 NORTH AMERICA LIPIDS MARKET, BY END USER

11.1 OVERVIEW

11.2 PHARMACEUTICAL INDUSTRIES

11.3 BIOTECHNOLOGY INDUSTRIES

11.4 COSMETIC INDUSTRIES

11.5 ACADEMIC AND RESEARCH INSTITUTES

11.6 OTHERS

12 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 OTHERS

13 NORTH AMERICA LIPIDS MARKET, BY REGION

13.1 NORTH AMERICA

13.1.1 U.S.

13.1.2 CANADA

13.1.3 MEXICO

14 NORTH AMERICA LIPIDS MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 BIONTECH SE.

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 MODERNA, INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 PFIZER INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 CARGILL, INCORPORATED.

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 KERRY.

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 ABITEC

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENTS

16.7 ADMSIO

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENTS

16.8 ALNYLAM PHARMACEUTICALS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BASF SE

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 CAYMAN CHEMICAL

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENTS

16.11 CD BIOPARTCLES.

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENTS

16.12 CHEMI S.P.A.

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENTS

16.13 CORDENPHARMA INTERNATIONAL

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 CRODA INTERNATIONAL PLC.

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 CURIA NORTH AMERICA, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 DSM

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENTS

16.17 EVONIK INDUSTRIES AG

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 GATTEFOSSÉ

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENTS

16.19 LIPOID GMBH

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 MATREYA, LLC

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

16.21 MERCK KGAA

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENTS

16.22 NOF EUROPE GMBH

16.22.1 COMPANY SNAPSHOT

16.22.2 PRODUCT PORTFOLIO

16.22.3 RECENT DEVELOPMENTS

16.23 STEPAN COMPANY

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT DEVELOPMENTS

16.24 TOKYO CHEMICAL INDUSTRY CO., LTD.

16.24.1 COMPANY SNAPSHOT

16.24.2 PRODUCT PORTFOLIO

16.24.3 RECENT DEVELOPMENTS

16.25 VAV LIFE SCIENCES PVT LTD

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 ASP FOR MAJOR DRUGS IN LIPIDS MARKET (PRICE IN USD)

TABLE 2 LIPID BASED NANO PARTICLE FOR COVID-19 VACCINES

TABLE 3 LIPID BASED NANO PARTICLE FOR CANCER VACCINES

TABLE 4 RNA ENCAPSULATED LIPID NANOPARTICLES

TABLE 5 LIPOSOMAL FORMULATIONS

TABLE 6 LIPID BASED NANO PARTICLE FOR COVID VACCINES

TABLE 7 LIPOSOMAL FORMULATION

TABLE 8 LIPID BASED NANO PARTICLE FOR CANCER VACCINES

TABLE 9 RNA ENCAPSULATED LIPID NANOPARTICLES

TABLE 10 LIPOSOME FORMULATIONS

TABLE 11 LIPID BASED NANO PARTICLE FOR COVID VACCINES

TABLE 12 LIPID BASED NANO PARTICLE FOR CANCER VACCINES

TABLE 13 LIPOSOMAL FORMULATION

TABLE 14 NORTH AMERICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA NATURAL LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA SYNTHETIC LIPID IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA SOLID LIPID NANOPARTICLES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA NANOSTRUCTURES LIPID CARRIER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA TRANSFEROSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA NIOSOMES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA PURIFIED FATTY ACIDS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA PURIFIED OILS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA EGG YOLK IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA NON-GMO SOYABEAN IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA PHARMACEUTICAL INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA BIOTECHNOLOGY INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA COSMETIC INDUSTRIES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA DIRECT TENDER IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA RETAIL SALES IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA OTHERS IN LIPIDS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA LIPIDS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 80 U.S. LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 81 U.S. NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 82 U.S. SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 83 U.S. LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 84 U.S. NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 85 U.S. BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 86 U.S. FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 87 U.S. BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 88 U.S. POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 89 U.S. HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 90 U.S. LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 91 U.S. LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 92 U.S. LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 93 U.S. REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 94 U.S. PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 95 U.S. LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)

TABLE 96 U.S. LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 97 U.S. LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 98 CANADA LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 99 CANADA NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 100 CANADA SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 101 CANADA LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 102 CANADA NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 103 CANADA BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 104 CANADA FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 105 CANADA BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 106 CANADA POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 107 CANADA HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 108 CANADA LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 109 CANADA LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 110 CANADA LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 111 CANADA REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 112 CANADA PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 113 CANADA LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)

TABLE 114 CANADA LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 CANADA LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 116 MEXICO LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 117 MEXICO NATURAL LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 118 MEXICO SYNTHETIC LIPIDS IN LIPIDS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 119 MEXICO LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 120 MEXICO NEUTRAL LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 121 MEXICO BACTERIAL LIPIDS IN LIPIDS MARKET, BY LIPIDS SYSTEMS, 2021-2030 (USD MILLION)

TABLE 122 MEXICO FLUORESCENT LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 123 MEXICO BIOACTIVE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 124 MEXICO POLYMERIZABLE LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 125 MEXICO HEADGROUP MODIFIED LIPIDS IN LIPIDS MARKET, BY LIPID SYSTEMS, 2021-2030 (USD MILLION)

TABLE 126 MEXICO LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 127 MEXICO LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 128 MEXICO LIPOSOMES FOR DNA/RNA IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 129 MEXICO REACTIVE LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 130 MEXICO PLAIN LIPOSOMES IN LIPIDS MARKET, BY DELIVERY SYSTEMS, 2021-2030 (USD MILLION)

TABLE 131 MEXICO LIPIDS MARKET, BY SOURCE, 2021-2030 (USD MILLION)

TABLE 132 MEXICO LIPIDS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 133 MEXICO LIPIDS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA LIPIDS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LIPIDS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LIPIDS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LIPIDS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LIPIDS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA LIPIDS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA LIPIDS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LIPIDS MARKET: SEGMENTATION

FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE NORTH AMERICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIPIDS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIPIDS MARKET

FIGURE 14 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2022

FIGURE 15 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 16 NORTH AMERICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 17 NORTH AMERICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022

FIGURE 19 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)

FIGURE 21 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE

FIGURE 22 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022

FIGURE 23 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)

FIGURE 24 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)

FIGURE 25 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE

FIGURE 26 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2022

FIGURE 27 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)

FIGURE 28 NORTH AMERICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)

FIGURE 29 NORTH AMERICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA LIPIDS MARKET: BY END USER, 2022

FIGURE 31 NORTH AMERICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 NORTH AMERICA LIPIDS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 NORTH AMERICA LIPIDS MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 NORTH AMERICA LIPIDS MARKET: SNAPSHOT (2022)

FIGURE 39 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022)

FIGURE 40 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 NORTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030)

FIGURE 43 NORTH AMERICA LIPIDS MARKET: COMPANY SHARE 2022 (%)

View Infographics

FIGURE 1 NORTH AMERICA LIPIDS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LIPIDS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LIPIDS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LIPIDS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LIPIDS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LIPIDS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LIPIDS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA LIPIDS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA LIPIDS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LIPIDS MARKET: SEGMENTATION

FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE NORTH AMERICA LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIPIDS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIPIDS MARKET

FIGURE 14 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2022

FIGURE 15 NORTH AMERICA LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 16 NORTH AMERICA LIPIDS MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 17 NORTH AMERICA LIPIDS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2022

FIGURE 19 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION)

FIGURE 20 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030)

FIGURE 21 NORTH AMERICA LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE

FIGURE 22 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022

FIGURE 23 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION)

FIGURE 24 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030)

FIGURE 25 NORTH AMERICA LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE

FIGURE 26 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2022

FIGURE 27 NORTH AMERICA LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION)

FIGURE 28 NORTH AMERICA LIPIDS MARKET: BY SOURCE, CAGR (2023-2030)

FIGURE 29 NORTH AMERICA LIPIDS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 30 NORTH AMERICA LIPIDS MARKET: BY END USER, 2022

FIGURE 31 NORTH AMERICA LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 NORTH AMERICA LIPIDS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 NORTH AMERICA LIPIDS MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 NORTH AMERICA LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 NORTH AMERICA LIPIDS MARKET: SNAPSHOT (2022)

FIGURE 39 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022)

FIGURE 40 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 NORTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030)

FIGURE 43 NORTH AMERICA LIPIDS MARKET: COMPANY SHARE 2022 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19